Construction of a Recombinant Mammalian Expression System for the Production of Human TGF-beta 1 and Members of TGF-beta Superfa
Posted Mar 31 2004 4:00pm
Description of Invention: Transforming growth factor-beta 1 (“TGF-beta 1”) is an anti-inflammatory cytokine and is widely used in immunological research. Various recombinant expression systems produce TGF-beta 1, however, the yield of such expression systems remains low with the most effective systems producing from 1-5 mg/liter of cell culture with lengthy purification steps. As a result, the availability and price of the cytokine is unsatisfactory.
To address this problem, this invention provides a novel mammalian recombinant TGF-beta expression system which produces TGF-beta 1 at approximately 30 mg/liter of cell culture, which is approximately 10 times better than the yield provided by existing recombinant TGF-beta 1 expression systems. Owing to the large superfamily of cytokines to which TGF-beta belongs, this expression system can be potentially applied to other members of the TGF-beta superfamily.
Inventors: Peter D Sun (NIAID) Zhongcheng Zou (NIAID)
Portfolios: Internal Medicine Internal Medicine - Therapeutics Internal Medicine - Research Materials Miscellaneous
For Additional Information Please Contact: David Lambertson Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: lambertsond@mail.nih.gov Phone: 301-435-4632 Fax: 301-402-0220
Description of Invention:
Transforming growth factor-beta 1 (“TGF-beta 1”) is an anti-inflammatory cytokine and is widely used in immunological research. Various recombinant expression systems produce TGF-beta 1, however, the yield of such expression systems remains low with the most effective systems producing from 1-5 mg/liter of cell culture with lengthy purification steps. As a result, the availability and price of the cytokine is unsatisfactory.
To address this problem, this invention provides a novel mammalian recombinant TGF-beta expression system which produces TGF-beta 1 at approximately 30 mg/liter of cell culture, which is approximately 10 times better than the yield provided by existing recombinant TGF-beta 1 expression systems. Owing to the large superfamily of cytokines to which TGF-beta belongs, this expression system can be potentially applied to other members of the TGF-beta superfamily.
Inventors:
Peter D Sun (NIAID)
Zhongcheng Zou (NIAID)
Patent Status:
HHS, Reference No. E-048-2004/2
US, Application No. 10/585,499 filed 06 Jul 2006
Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Internal Medicine - Research Materials
Miscellaneous
For Additional Information Please Contact:
David Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: lambertsond@mail.nih.gov
Phone: 301-435-4632
Fax: 301-402-0220
Ref No: 919
Updated: 04/2004